Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
PURPOSE: To determine the impact familial prostate cancer has on prognosis in men treated with brachytherapy for clinically localized prostate cancer.
METHODS AND MATERIALS: A total of 1,738 consecutive patients with prostate cancer (cT1-3, N0/X, M0) received low-dose-rate brachytherapy alone or in combination with external beam radiation therapy or hormone ablation from 1992 to 2005. The primary end-point was freedom from biochemical failure (FFBF) using the Phoenix definition. Minimum follow-up was 2 years and the median follow-up was 60 months (range, 24-197 months).
RESULTS: A total of 187 of 1,738 men (11%) had a family history of prostate cancer in a first-degree relative. For the low-risk patients, both groups had similar actuarial 5-year FFBF (97.2% vs. 95.5%, p = 0.516). For intermediate-risk patients, there was a trend toward improved biochemical control in men positive for family history (5-yr FFBF 100% vs. 93.6%, p = 0.076). For the high-risk patients, men with a positive family history had similar 5-year FFBF (92.8% vs. 85.2%, p = 0.124). On multivariate analysis, family history was not significant; use of hormones, high biologic effective dose, initial prostate-specific antigen value, and Gleason score were the significant variables predicting biochemical control.
CONCLUSIONS: This is the first study to examine the relationship of familial prostate cancer and outcomed in men treated with brachytherapy alone or in combination therapy. Men with a positive family history have clinicopathologic characteristics and biochemical outcomes similar to those with sporadic disease.
Published In/Presented At
Peters, C. A., Stock, R. G., Blacksburg, S. R., & Stone, N. N. (2009). Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer. International journal of radiation oncology, biology, physics, 73(1), 24–29. https://doi.org/10.1016/j.ijrobp.2008.04.031
Medicine and Health Sciences | Oncology
Department of Radiation Oncology